Raloxifene Inhibits NF-kB Pathway and Potentiates Anti-Tumour Activity of Cisplatin with Simultaneous Reduction in its Nephrotoxictiy

Pathology and Oncology Research

Volumn 22, Issue 1, 2016, Pages 145-153

  Jamdade, Vinayak Sudhir ^a   Mundhe, Nitin A ^a   Kumar, Parveen ^a   Tadla, Venkatesh ^a   Lahkar, Mangala ^a,b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b GAUHATI MEDICAL COLLEGE   (India)

Author keywords

Cisplatin; Inflammation; Nephrotoxicity; Pro inflammatory cytokines; Raloxifene

Indexed keywords

ALBUMIN; CISPLATIN; CREATININE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; NITROGEN; RALOXIFENE; TUMOR NECROSIS FACTOR ALPHA; UREA; 7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTINEOPLASTIC AGENT; BONE DENSITY CONSERVATION AGENT;

ADULT; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG POTENTIATION; FEMALE; INHIBITION KINETICS; KIDNEY INJURY; NEPHROTOXICITY; NONHUMAN; RAT; SIGNAL TRANSDUCTION; TUMOR VOLUME; UREA NITROGEN BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; INFLAMMATION; KIDNEY DISEASES; MAMMARY NEOPLASMS, ANIMAL; METABOLISM; PATHOLOGY; WISTAR RAT;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; CISPLATIN; DRUG SYNERGISM; FEMALE; INFLAMMATION; KIDNEY DISEASES; MAMMARY NEOPLASMS, ANIMAL; NF-KAPPA B; RALOXIFENE HYDROCHLORIDE; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 84951574298     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-015-9988-6     Document Type: Article

References (31)

1. Bogdanovic G, Kojic V, Srdic T, Jakimov D, Djuran MI, Bugarcic ZD, Baltic M, Baltic VV (2002) Growth effects of some platinum(II) complexes with sulfur-containing carrier ligands on MCF7 human breast cancer cell line upon simultaneous administration with taxol. Met Based Drugs 9:33–43
2. Aisner J, Jacobs M, Sinabaldi V, Gray W, Eisenberger M (1994) Chemoradiotherapy for the treatment of regionally advanced head and neck cancers. Semin Oncol 21:35–44
3. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573–584
4. Ali BH, Al Moundhri MS (2006) Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 44:1173–1183
5. Ramesh G, Kimball SR, Jefferson LS, Reeves WB (2007) Endotoxin and cisplatin synergistically stimulate TNF-alpha production by renal epithelial cells. Am J Physiol Renal Physiol 292:F812–F819
6. Basnakian AG, Apostolov EO, Yin X, Napirei M, Mannherz HG, Shah SV (2005) Cisplatin nephrotoxicity is mediated by deoxyribonuclease I. J Am Soc Nephrol 16:697–702
7. Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460–464
8. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL (2007) Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 322:8–15
9. Ramesh G, Brian Reeves W (2006) Cisplatin increases TNF-alpha mRNA stability in kidney proximal tubule cells. Ren Fail 28:583–592
10. Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115–124
11. Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835–842
12. Ramesh G, Reeves WB (2003) TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 285:F610–F618
13. Ramesh G, Reeves WB (2004) Salicylate reduces cisplatin nephrotoxicity by inhibition of tumour necrosis factor-alpha. Kidney Int 65:490–499
14. Dong Z, Atherton SS (2007) Tumour necrosis factor-alpha in cisplatin nephrotoxicity: a homebred foe? Kidney Int 72:5–7
15. Kaya H, Ozkaya O, Sezik M, Arslanoglu E, Yilmaztepe A, Ulukaya E (2005) Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women. Maturitas 50:182–188
16. Lippuner K, Buchard PA, De Geyter C, Imthurn B, Lamy O, Litschgi M, Luzuy F, Schiessl K, Stute P, Birkhauser M (2012) Recommendations for raloxifene use in daily clinical practice in the Swiss setting. Eur Spine J 21:2407–2417
17. Shibata MA, Morimoto J, Shibata E, Kurose H, Akamatsu K, Li ZL, Kusakabe M, Ohmichi M, Otsuki Y (2010) Raloxifene inhibits tumour growth and lymph node metastasis in a xenograft model of metastatic mammary cancer. BMC Cancer 10:566
18. Galien R, Garcia T (1997) Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res 25:2424–2429
19. Olivier S, Close P, Castermans E, de Leval L, Tabruyn S, Chariot A, Malaise M, Merville MP, Bours V, Franchimont N (2006) Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature. Mol Pharmacol 69:1615–1623
20. K.K. Thakur, N.B. Bolshette, C. Trandafir, V.S. Jamdade, A. Istrate, R. Gogoi, A. Cucuianu, Role of toll-like receptors in multiple myeloma and recent advances. Exp Hematol (2014) 43(3):158–167
21. Kumar P, Bolshette NB, Jamdade VS, Mundhe NA, Thakur KK, Saikia KK, Lahkar M (2013) Breast cancer status in India: an overview. J Carcinog 3:177–183
22. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I, Hampson G (2003) Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J Endocrinol 177:423–433
23. Deng J, Kohda Y, Chiao H, Wang Y, Hu X, Hewitt SM, Miyaji T, McLeroy P, Nibhanupudy B, Li S, Star RA (2001) Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 60:2118–2128
24. Kalaitzidis D, Gilmore TD (2005) Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol Metab 16:46–52
25. Kumar P, Kadakol A, Shasthrula P, Mundhe NA, Jamdade VS, Barua CC, Gaikwad AB (2015) Curcumin as an adjuvant to breast cancer treatment. Anti Cancer Agents Med Chem 15:647–656
26. T. Whitsett, M. Carpinter, C.A. Lamartiniere (2006) Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J Carcinog 5 15.
27. Stuhr LE, Iversen VV, Straume O, Maehle BO, Reed RK (2004) Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors. Cancer Lett 210(1):35–40
28. Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H, Iida M (2003) Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney Int 63:72–82
29. Liu Y, Webb HK, Fukushima H, Micheli J, Markova S, Olson JL, Kroetz DL (2012) Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor kappaB signaling. J Pharmacol Exp Ther 341:725–734
30. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2:2490–2518
31. Schrier RW (2002) Cancer therapy and renal injury. J Clin Invest 110:743–745